FDA Updates Leqvio Label to Recognize LDL-C Reduction Lowers Cardiovascular Event Risk
核心洞察
The FDA updated the Leqvio (inclisiran) label to recognize that lowering low-density lipoprotein cholesterol (LDL-C (搜索)) reduces the risk of major adverse cardiovascular events (MACE) in adults at increased cardiovascular risk.
Novartis continues to advance its clinical trial program with more than 60,000 patients enrolled, and expects readouts for two trials evaluating secondary outcomes in CY27.
The label update strengthens the clinical positioning of Leqvio, a small interfering RNA (siRNA) therapy, within the cardiovascular risk-reduction treatment landscape.
Novartis announced that the U.S. Food and Drug Administration (FDA) has updated the label for Leqvio (inclisiran) to recognize that lowering low-density lipoprotein cholesterol (LDL-C (搜索)) reduces the risk of major adverse cardiovascular events (MACE) in adults at increased cardiovascular risk. The development was reported in the twenty-second edition of Emkay Global Financial Services' Pharma Weekly – In Case You Missed It, covering the week ending 23-Aug-26.
The label update represents a meaningful regulatory milestone for Leqvio, as it formally links the therapy's LDL-C (搜索)-lowering effect to a reduction in cardiovascular event risk, a clinically significant endpoint for patients at elevated cardiovascular risk.
Novartis continues to advance its clinical trial program for Leqvio, with more than 60,000 patients enrolled across its studies. The company expects readouts for two trials evaluating secondary outcomes in CY27, which could provide further evidence supporting the therapy's cardiovascular benefit profile.
The development carries read-through implications for Anthem (搜索), as noted in the Emkay Global Financial Services report. Leqvio is a small interfering RNA (siRNA)-based therapy that lowers LDL-C (搜索) through a mechanism distinct from traditional statins and other lipid-lowering agents, positioning it within the evolving landscape of cardiovascular risk management.
The label update underscores the growing body of evidence linking LDL-C (搜索) reduction to improved cardiovascular outcomes, reinforcing the therapeutic rationale for aggressive lipid management in at-risk adult populations.